Teachers Retirement System of The State of Kentucky Has $7.83 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Teachers Retirement System of The State of Kentucky lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 93,388 shares of the biopharmaceutical company's stock after selling 5,779 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Gilead Sciences were worth $7,830,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Bellevue Group AG boosted its stake in shares of Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock worth $3,859,000 after acquiring an additional 7,093 shares in the last quarter. Quantinno Capital Management LP boosted its position in Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock worth $6,843,000 after purchasing an additional 48,910 shares in the last quarter. Legal & General Group Plc grew its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares during the last quarter. IRON Financial LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at $830,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Gilead Sciences by 12.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company's stock worth $27,081,000 after buying an additional 36,895 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 447,234 shares of company stock worth $41,288,086 over the last 90 days. Insiders own 0.16% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Royal Bank of Canada reissued a "sector perform" rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday. Leerink Partners upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and increased their price target for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Robert W. Baird lifted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Sanford C. Bernstein began coverage on Gilead Sciences in a report on Thursday, October 17th. They set an "outperform" rating and a $105.00 target price on the stock. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $96.43.

Gilead Sciences Trading Up 0.3 %

GILD traded up $0.24 during trading on Friday, reaching $91.86. The company had a trading volume of 6,888,210 shares, compared to its average volume of 7,068,425. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The firm's 50-day simple moving average is $89.82 and its 200 day simple moving average is $79.26. The company has a market cap of $114.48 billion, a price-to-earnings ratio of 1,026.44, a PEG ratio of 2.38 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the business earned $2.29 EPS. The business's revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.35%. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.